MariMed Restructures $14.2M Obligation, Issues $8M in New Notes and Convertible Preferred Stock

summarizeSummary

MariMed Inc. has restructured a $14.2 million mandatory cash payment obligation, replacing it with $8 million in new promissory notes and 26.9 million shares of new convertible preferred stock.

check_boxKey Events

• Critical Obligation Extinguished

  The company faced a mandatory $14.2 million cash payment on February 28, 2026, related to the conversion of its original Series B Preferred Stock. This obligation has been extinguished through a new Restructuring and Exchange Agreement.

• New Debt Issued

  MariMed issued two new promissory notes totaling $8 million to Navy Capital. Note #1 is for $2 million due March 1, 2028, at 8.0% interest, and Note #2 is for $6 million due March 1, 2031, at 10.0% interest (reducible to 8% if Note #1 is paid early). These notes are guaranteed by certain subsidiaries.

• New Convertible Preferred Stock Issued

  The company issued 26.9 million shares of new Series B Convertible Preferred Stock to Navy Capital. These shares have an aggregate liquidation preference of $6.725 million ($0.25 per share) and are convertible into common stock on a one-for-one basis at the holder's option.

• Potential Dilution from Preferred Stock

  If all 26.9 million shares of the new Series B Preferred Stock were converted into common stock, it would represent a potential dilution of approximately 6.77% based on the current outstanding common shares.

auto_awesomeAnalysis

MariMed Inc., a micro-cap company, has successfully restructured a critical $14.2 million cash obligation that was due on February 28, 2026. This obligation, stemming from the mandatory conversion of old Series B Preferred Stock, represented a substantial portion of the company's market capitalization. The new Restructuring and Exchange Agreement with Navy Capital extinguishes this immediate cash threat. In its place, MariMed has issued $8 million in new promissory notes with maturities in 2028 and 2031 (accruing 8-10% interest) and 26.9 million shares of new Series B Convertible Preferred Stock. While the new preferred stock carries a liquidation preference of $0.25 per share (significantly above the current common stock price of $0.081) and introduces potential dilution of approximately 6.77% if fully converted, the immediate financial pressure has been alleviated. This move is crucial for the company's short-term financial stability and operational runway.